We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

LXR

Liver X receptor (LXR) agonists and antagonists act on oxysterol-activated nuclear receptors. LXRα and LXRβ were shown in 1996 to respond to oxidized cholesterol derivatives such as 24,25-epoxycholesterol. Through sterol regulatory element-binding protein 1c (SREBP-1c) they link sterol sensing to fatty acid synthesis in liver, and they also drive genes of reverse cholesterol transport. GW3965 and GW3965 HCl are synthetic agonists of both subtypes and are widely used in such gene expression work. T0901317 activates LXR but also acts on the farnesoid X receptor, so selectivity controls matter. GSK-2033 acts as an antagonist and SR9243 as an inverse agonist, which allows loss-of-function comparisons in the same system.

1 Item

  • GAC0003A4
    Cat. No.
    A76527
    CAS No.
    929492-71-7

    GAC0003A4

    GAC0003A4 is an LXR (liver X receptor) degrader that inhibits LXR transcriptional activity. It effectively promotes the degradation of LXRβ protein, thereby decreasing its biological function. This compound shows potential for research applications in advanced pancreatic cancer and other refractory malignancies, making it a valuable tool for studying LXR-related pathways in cancer biology.

    In stock View Details
    1 mg
    $55.00
    5 mg
    $135.00
    All 7 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...